IRVINE, Calif.--(BUSINESS WIRE)--Jan. 29, 2019--
Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative
treatments for aortic disorders, today announced that it will report
financial results for the fourth quarter and fiscal year 2018 after the
market close on Monday, February 25, 2019. The Company’s management will
host a conference call at 4:30 p.m. ET that same day to discuss the
To participate in the conference call, dial 877-407-9716 (domestic) or
201-493-6779 (international) and refer to the passcode 13687136.
This conference call will also be webcast and can be accessed from the
“Investors” section of the Company’s website at www.endologix.com.
The webcast replay of the call will be available at the same site
approximately one hour after the end of the call.
A recording of the call will also be available from 7:30 p.m. ET on
Monday, February 25, 2019, until 11:59 p.m. ET on Monday, March 4, 2019.
To hear this recording, dial 844-512-2921 (domestic) or 412-317-6671
(international) and enter the passcode 13687136.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments
for aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it continues
to enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the United
States. For more information, visit www.endologix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190129005804/en/
Vaseem Mahboob, CFO